{"id":922660,"date":"2025-12-29T08:15:01","date_gmt":"2025-12-29T13:15:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/"},"modified":"2025-12-29T08:15:01","modified_gmt":"2025-12-29T13:15:01","slug":"genmab-portfolio-prioritization-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/","title":{"rendered":"Genmab Portfolio Prioritization Update"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Genmab Portfolio Prioritization Update<\/b><\/p>\n<p><b>Company Announcement<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Genmab to discontinue clinical development of acasunlimab following a portfolio review<\/b><\/li>\n<li><b>Decision reflects prioritization of higher\u2011impact opportunities across Genmab\u2019s late\u2011stage pipeline and increasingly competitive landscape<\/b><\/li>\n<li><b>This decision does not impact Genmab\u2019s full\u2011year 2025 financial guidance<\/b><\/li>\n<\/ul>\n<p>COPENHAGEN, Denmark&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.genmab.com&amp;esheet=54385396&amp;newsitemid=20251229382114&amp;lan=en-US&amp;anchor=Genmab+A%2FS&amp;index=1&amp;md5=8266eea95848055c3f0f2e1aa06c1978\"><b>Genmab A\/S<\/b><\/a><b> (Nasdaq: GMAB) announced today that<\/b><b>it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab\u2019s strategic focus on the most value\u2011creating opportunities in its late\u2011stage portfolio and following a thorough assessment of the evolving competitive landscape. <\/b>While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including EPKINLY<sup>\u00ae<\/sup> (epcoritamab), petosemtamab and rinatabart sesutecan (Rina\u2011S<sup>\u00ae<\/sup>), which are advancing in late\u2011stage development. This decision is consistent with Genmab\u2019s disciplined portfolio prioritization and capital allocation framework.<\/p>\n<p>\n\u201cAfter careful consideration, we have decided to discontinue the acasunlimab program. Although the data have been encouraging, the compelling opportunities we see in our late\u2011stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders. We are highly energized by the momentum of EPKINLY, petosemtamab and Rina\u2011S, and we remain committed to executing these programs with speed and rigor,\u201d said Jan van de Winkel, Ph.D., Chief Executive Officer, Genmab.<\/p>\n<p>\nThis decision does not impact Genmab\u2019s full\u2011year 2025 financial guidance.<\/p>\n<p><b>About Genmab<br \/>\n<br \/><\/b>Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody\u2013drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab\u2019s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.<\/p>\n<p>\nEstablished in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DPxrb0jBGEpZVp5eQVRx92jNkmaVSsts0_MldrdZ96_VEBSpwK86DMOhrQEQ7wJMOQrfb4EOk4fpGk74y49QyYw%3D%3D&amp;esheet=54385396&amp;newsitemid=20251229382114&amp;lan=en-US&amp;anchor=Genmab.com&amp;index=2&amp;md5=8c64a4f5c66de722d21ec44de4580c5e\">Genmab.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgenmab&amp;esheet=54385396&amp;newsitemid=20251229382114&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=d4c44bf66820e1f0b7cf4e7fb0e2c486\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FGenmab&amp;esheet=54385396&amp;newsitemid=20251229382114&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=72b329f30d8362fa7290e58e091f641b\">X<\/a>.<\/p>\n<p><i>This Company Announcement contains forward looking statements. The words \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend\u201d and \u201cplan\u201d and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab\u2019s most recent financial reports, which are available on <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.genmab.com%2F&amp;esheet=54385396&amp;newsitemid=20251229382114&amp;lan=en-US&amp;anchor=www.genmab.com&amp;index=5&amp;md5=6f85c452ef70571549bc5b807dceaaba\"><i>www.genmab.com<\/i><\/a><i \/><i>and the risk factors included in Genmab\u2019s most recent Annual Report on Form 20-F and other filings <\/i><i>with the U.S. Securities and Exchange Commission (SEC), which are available at <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2Fsearch-filings&amp;esheet=54385396&amp;newsitemid=20251229382114&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=9a4a2c8f9627260bf42ed0e594865083\"><i>www.sec.gov<\/i><\/a><i>. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.<\/i><\/p>\n<p><i>Genmab A\/S and\/or its subsidiaries own the following trademarks: Genmab<sup>\u00ae<\/sup>; the Y-shaped Genmab logo<sup>\u00ae<\/sup>; Genmab in combination with the Y-shaped Genmab logo<sup>\u00ae<\/sup>; HuMax<sup>\u00ae<\/sup>; DuoBody<sup>\u00ae<\/sup>; HexaBody<sup>\u00ae<\/sup>; DuoHexaBody<sup>\u00ae<\/sup>, HexElect<sup>\u00ae <\/sup>and KYSO<\/i><sup>\u00ae<\/sup><i>. Rina-S<sup>\u00ae<\/sup> is a trademark of ProfoundBio, US, Co. and Genmab (Suzhou) Co., Ltd.; EPKINLY<\/i><sup>\u00ae<\/sup><i> and its design are trademarks of AbbVie Biotechnology Ltd.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251229382114\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251229382114\/en\/<\/a><\/span><\/p>\n<p>\nMarisol Peron, Senior Vice President, Global Communications &amp; Corporate Affairs<br \/>\n<br \/>T: +1 609 524 0065; E: <a rel=\"nofollow\" href=\"mailto:mmp@genmab.com\">mmp@genmab.com<\/a><\/p>\n<p>\nAndrew Carlsen, Vice President, Head of Investor Relations<br \/>\n<br \/>T: +45 3377 9558; E: <a rel=\"nofollow\" href=\"mailto:acn@genmab.com\">acn@genmab.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Denmark Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251229382114\/en\/2679022\/3\/Genmab_Logo_Color_RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Genmab Portfolio Prioritization Update Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher\u2011impact opportunities across Genmab\u2019s late\u2011stage pipeline and increasingly competitive landscape This decision does not impact Genmab\u2019s full\u2011year 2025 financial guidance COPENHAGEN, Denmark&#8211;(BUSINESS WIRE)&#8211;Genmab A\/S (Nasdaq: GMAB) announced today thatit will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab\u2019s strategic focus on the most value\u2011creating opportunities in its late\u2011stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including EPKINLY\u00ae (epcoritamab), petosemtamab and rinatabart sesutecan (Rina\u2011S\u00ae), which are advancing in late\u2011stage &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Genmab Portfolio Prioritization Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-922660","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genmab Portfolio Prioritization Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genmab Portfolio Prioritization Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Genmab Portfolio Prioritization Update Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher\u2011impact opportunities across Genmab\u2019s late\u2011stage pipeline and increasingly competitive landscape This decision does not impact Genmab\u2019s full\u2011year 2025 financial guidance COPENHAGEN, Denmark&#8211;(BUSINESS WIRE)&#8211;Genmab A\/S (Nasdaq: GMAB) announced today thatit will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab\u2019s strategic focus on the most value\u2011creating opportunities in its late\u2011stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including EPKINLY\u00ae (epcoritamab), petosemtamab and rinatabart sesutecan (Rina\u2011S\u00ae), which are advancing in late\u2011stage &hellip; Continue reading &quot;Genmab Portfolio Prioritization Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T13:15:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genmab Portfolio Prioritization Update\",\"datePublished\":\"2025-12-29T13:15:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/\"},\"wordCount\":729,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/\",\"name\":\"Genmab Portfolio Prioritization Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-12-29T13:15:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-portfolio-prioritization-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genmab Portfolio Prioritization Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genmab Portfolio Prioritization Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/","og_locale":"en_US","og_type":"article","og_title":"Genmab Portfolio Prioritization Update - Market Newsdesk","og_description":"Genmab Portfolio Prioritization Update Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher\u2011impact opportunities across Genmab\u2019s late\u2011stage pipeline and increasingly competitive landscape This decision does not impact Genmab\u2019s full\u2011year 2025 financial guidance COPENHAGEN, Denmark&#8211;(BUSINESS WIRE)&#8211;Genmab A\/S (Nasdaq: GMAB) announced today thatit will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab\u2019s strategic focus on the most value\u2011creating opportunities in its late\u2011stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including EPKINLY\u00ae (epcoritamab), petosemtamab and rinatabart sesutecan (Rina\u2011S\u00ae), which are advancing in late\u2011stage &hellip; Continue reading \"Genmab Portfolio Prioritization Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-29T13:15:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genmab Portfolio Prioritization Update","datePublished":"2025-12-29T13:15:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/"},"wordCount":729,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/","name":"Genmab Portfolio Prioritization Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-12-29T13:15:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251229382114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-portfolio-prioritization-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genmab Portfolio Prioritization Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/922660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=922660"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/922660\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=922660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=922660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=922660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}